PMID- 32033527 OWN - NLM STAT- MEDLINE DCOM- 20201130 LR - 20221207 IS - 1471-2296 (Electronic) IS - 1471-2296 (Linking) VI - 21 IP - 1 DP - 2020 Feb 7 TI - Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial. PG - 26 LID - 10.1186/s12875-020-1096-3 [doi] LID - 26 AB - BACKGROUND: Vitamin D (VD) may increase sirtuin 1 (SIRT1) and subsequently PPAR-gamma coactivator 1alpha (PGC-1alpha) and irisin levels and these improvements may reduce insulin resistance (IR). The aim was to assess the effects of vitamin D supplementation on SIRT1, irisin, and IR in overweight/obese type 2 diabetes (T2D) patients. METHODS: Ninety T2D males and females were recruited as a clinical trial study (mean of age and body mass index (BMI) of intervention and placebo groups were 50.05 +/- 10.17 and 50.36 +/- 10.2 yrs. and 31.37 +/- 3.4 and 30.43 +/- 3.2 kg/m(2), respectively). The inclusion criteria were T2D, VD deficient, BMI > 25 kg/m(2), and serum HbA1c < 8.5%. The exclusion criteria were using vitamin and mineral supplements, having any acute disease, recent modifying dose or type of drugs. The supplementation was 50,000 IU/week VD or placebo for 8 weeks. The demographic characteristics, anthropometrics, dietary intakes and physical activity status, sun exposure status, fasting blood sugar (FBS) and insulin, glycosylated hemoglobin (HbA1c), irisin, SIRT1, 25-hydroxy D3 (25(OH)VD), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI) were determined. The significant P-value was